{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:15:44Z","timestamp":1783394144895,"version":"3.54.6"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Given the limited real-world evidence on finerenone in patients with diabetic kidney disease (DKD), particularly with preserved renal function, this study aimed to evaluate the effectiveness and safety of finerenone in DKD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 127 patients with DKD treated with finerenone, including those with preserved renal function. Changes from baseline in the urine albumin-to-creatinine ratio (UACR), urinary microalbumin (mALB), urinary protein semi-quantitative, urinary N-acetyl-\u03b2-D-glucosaminidase (NAG) and estimated glomerular filtration rate (eGFR) were evaluated at 1, 3, and 6 months post-treatment. The safety profile was recorded during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Following treatment with finerenone, the median UACR was significantly reduced from a baseline of 100\u00a0mg\/g to 59\u00a0mg\/g, 48\u00a0mg\/g, and 43\u00a0mg\/g at 1, 3, and 6 months, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 for 1 and 3 months). Similarly, mALB levels significantly decreased over the same period (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Stratified analysis revealed that the mean UACR reduction at 1, 3, and 6 months was 35%, 33%, and 21% in stage A2 patients, while it was 44%, 58%, and 57% in stage A3 patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Moreover, finerenone significantly improved UACR staging classification, while also reducing both the proportion of proteinuria (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and urinary NAG levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). In terms of safety, eGFR exhibited an initial decline followed by a subsequent rise (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.117). Three patients (2.4%) experienced hyperkalemia, and one patient discontinued treatment due to a decrease in eGFR of more than 30%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Finerenone demonstrated a significant reduction in proteinuria in DKD patients, particularly in patients with UACR stage A3, with a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05035-4","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:54:38Z","timestamp":1778561678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of finerenone in diabetic kidney disease with preserved eGFR: a retrospective study in China"],"prefix":"10.1186","volume":"27","author":[{"given":"Yiru","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"11","key":"5035_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","volume":"17","author":"M Oshima","year":"2021","unstructured":"Oshima M, et al. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol. 2021;17(11):740\u201350.","journal-title":"Nat Rev Nephrol"},{"key":"5035_CR2","doi-asserted-by":"publisher","first-page":"1407348","DOI":"10.3389\/fendo.2024.1407348","volume":"15","author":"W Xu","year":"2024","unstructured":"Xu W, et al. Risk prediction models for diabetic nephropathy among type 2 diabetes patients in China: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024;15:1407348.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"5035_CR3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"5035_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/ndt\/gfad215","volume":"39","author":"Z Makhammajanov","year":"2024","unstructured":"Makhammajanov Z, et al. Tubular toxicity of proteinuria and the progression of chronic kidney disease. Nephrol Dial Transpl. 2024;39(4):589\u201399.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"5035_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2023.04.015","volume":"82","author":"RB Albakr","year":"2023","unstructured":"Albakr RB, Sridhar VS, Cherney DZI. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials. Am J Kidney Dis. 2023;82(6):737\u201342.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"5035_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","volume":"102","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102(2):248\u201360.","journal-title":"Kidney Int"},{"key":"5035_CR7","doi-asserted-by":"crossref","unstructured":"Georgianos PI, et al. Therapeutic advances in diabetic kidney disease. Int J Mol Sci. 2023;24(3).","DOI":"10.3390\/ijms24032803"},{"issue":"5","key":"5035_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"5035_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","volume":"119","author":"M Epstein","year":"2006","unstructured":"Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119(11):912\u20139.","journal-title":"Am J Med"},{"issue":"4","key":"5035_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98(4):1063\u20138.","journal-title":"J Clin Invest"},{"issue":"3","key":"5035_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ajh\/hpac124","volume":"36","author":"PI Georgianos","year":"2023","unstructured":"Georgianos PI, Agarwal R. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature. Am J Hypertens. 2023;36(3):135\u201343.","journal-title":"Am J Hypertens"},{"issue":"23","key":"5035_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"6","key":"5035_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"24","key":"5035_CR14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"key":"5035_CR15","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1\u2013S127.","DOI":"10.1016\/j.kint.2022.06.008"},{"issue":"10","key":"5035_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"L Blonde","year":"2022","unstructured":"Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923\u20131049.","journal-title":"Endocr Pract"},{"issue":"2","key":"5035_CR17","doi-asserted-by":"publisher","first-page":"2400541","DOI":"10.1080\/0886022X.2024.2400541","volume":"46","author":"J Zhou","year":"2024","unstructured":"Zhou J, et al. Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China. Ren Fail. 2024;46(2):2400541.","journal-title":"Ren Fail"},{"key":"5035_CR18","doi-asserted-by":"publisher","first-page":"100294","DOI":"10.1016\/j.metop.2024.100294","volume":"22","author":"A Mima","year":"2024","unstructured":"Mima A, et al. Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease. Metabol Open. 2024;22:100294.","journal-title":"Metabol Open"},{"key":"5035_CR19","doi-asserted-by":"publisher","first-page":"100318","DOI":"10.1016\/j.metop.2024.100318","volume":"24","author":"Y Kawaguchi","year":"2024","unstructured":"Kawaguchi Y, et al. Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study. Metabol Open. 2024;24:100318.","journal-title":"Metabol Open"},{"issue":"8","key":"5035_CR20","first-page":"762","volume":"13","author":"MCGoCD Society","year":"2021","unstructured":"Society MCGoCD. Clincal Guideline for the Prevention and Treatment of Diabetic Kidney Disease in China (2021 edition)s. Chin J Diabetes Mellitus. 2021;13(8):762\u201384.","journal-title":"Chin J Diabetes Mellitus"},{"issue":"2","key":"5035_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJM198407123110204","volume":"311","author":"CE Mogensen","year":"1984","unstructured":"Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311(2):89\u201393.","journal-title":"N Engl J Med"},{"issue":"6","key":"5035_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1056\/NEJM198402093100605","volume":"310","author":"CE Mogensen","year":"1984","unstructured":"Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"5035_CR23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","volume":"80","author":"M Epstein","year":"2022","unstructured":"Epstein M, et al. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms. Am J Kidney Dis. 2022;80(5):658\u201366.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"5035_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","volume":"18","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, et al. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022;18(1):56\u201370.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"5035_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","volume":"78","author":"D Hirohama","year":"2021","unstructured":"Hirohama D, et al. Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db\/db Mice. Hypertension. 2021;78(1):82\u201393.","journal-title":"Hypertension"},{"issue":"1","key":"5035_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"5035_CR27","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340.","journal-title":"J Endocrinol"},{"issue":"27","key":"5035_CR28","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u201314.","journal-title":"Eur Heart J"},{"issue":"6","key":"5035_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022;145(6):437\u201347.","journal-title":"Circulation"},{"issue":"13","key":"5035_CR30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/eurheartj\/ehac683","volume":"44","author":"LM Ruilope","year":"2023","unstructured":"Ruilope LM, et al. Prevention of cardiorenal damage: importance of albuminuria. Eur Heart J. 2023;44(13):1112\u201323.","journal-title":"Eur Heart J"},{"key":"5035_CR31","doi-asserted-by":"publisher","first-page":"112189","DOI":"10.1016\/j.diabres.2025.112189","volume":"224","author":"M Di Marco","year":"2025","unstructured":"Di Marco M, et al. Triglycerides to high density lipoprotein cholesterol ratio (TG\/HDL), but not triglycerides and glucose product (TyG) index, is associated with arterial stiffness in prediabetes. Diabetes Res Clin Pract. 2025;224:112189.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"5035_CR32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9):884\u201394.","journal-title":"JAMA"},{"issue":"1","key":"5035_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/ki.2014.98","volume":"86","author":"RJ MacIsaac","year":"2014","unstructured":"MacIsaac RJ, Ekinci EI, Jerums G. Progressive diabetic nephropathy. How useful is microalbuminuria? contra. Kidney Int. 2014;86(1):50\u20137.","journal-title":"Kidney Int"},{"key":"5035_CR34","doi-asserted-by":"publisher","first-page":"204201881989111","DOI":"10.1177\/2042018819891110","volume":"10","author":"Y Qin","year":"2019","unstructured":"Qin Y, et al. Evaluation of urinary biomarkers for prediction of diabetic kidney disease: a propensity score matching analysis. Ther Adv Endocrinol Metab. 2019;10:2042018819891110.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"5035_CR35","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s11255-023-03843-3","volume":"56","author":"S dos Bitencourt","year":"2024","unstructured":"dos Bitencourt S. Evaluation of N-acetyl-\u03b2-D-glucosaminidase as a prognostic marker for diabetic nephropathy in type 2 diabetics: systematic review and meta-analysis. Int Urol Nephrol. 2024;56(5):1651\u201361.","journal-title":"Int Urol Nephrol"},{"key":"5035_CR36","doi-asserted-by":"publisher","first-page":"102946","DOI":"10.1016\/j.redox.2023.102946","volume":"68","author":"L Yao","year":"2023","unstructured":"Yao L, et al. Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy. Redox Biol. 2023;68:102946.","journal-title":"Redox Biol"},{"issue":"9","key":"5035_CR37","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1111\/liv.16005","volume":"44","author":"S Scilletta","year":"2024","unstructured":"Scilletta S, et al. Acute hyperbilirubinemia determines an early subclinical renal damage: Evaluation of tubular biomarkers in cholemic nephropathy. Liver Int. 2024;44(9):2341\u201350.","journal-title":"Liver Int"},{"key":"5035_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pcad.2025.05.008","volume":"92","author":"G Bosco","year":"2025","unstructured":"Bosco G, et al. Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Prog Cardiovasc Dis. 2025;92:108\u201317.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"5035_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11883-024-01271-x","volume":"27","author":"F Di Giacomo-Barbagallo","year":"2025","unstructured":"Di Giacomo-Barbagallo F, et al. Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field. Curr Atheroscler Rep. 2025;27(1):25.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"5035_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"5035_CR41","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05035-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:49:43Z","timestamp":1783392583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05035-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5035"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05035-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the Ethics Committee due to the retrospective nature of the study. The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (Approval No.: IIT [2024] Clinical Ethical Review No. 634).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}